Paolo Artioli
Overview
Explore the profile of Paolo Artioli including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
5
Citations
76
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Matrone F, Urso L, Girometti R, Polesel J, Sepulcri M, Pierantoni F, et al.
Ther Adv Urol
. 2025 Mar;
17:17562872251321971.
PMID: 40083770
Background: Next-generation imaging (NGI) technologies such as multiparametric magnetic resonance imaging (mpMRI) and total-body NGI (tbNGI) methodologies including choline, fluciclovine or PSMA positron emission tomography/computed tomography (PET/CT), whole-body MRI (wbMRI),...
2.
Urso L, Nieri A, Uccelli L, Castello A, Artioli P, Cittanti C, et al.
Pharmaceutics
. 2023 Apr;
15(4).
PMID: 37111596
Lutathera is the first EMA- and FDA-approved radiopharmaceutical for radioligand therapy (RLT). Currently, on the legacy of the NETTER1 trial, only adult patients with progressive unresectable somatostatin receptor (SSTR) positive...
3.
Urso L, Lancia F, Ortolan N, Frapoli M, Rauso M, Artioli P, et al.
Clin Transl Imaging
. 2022 Aug;
10(6):687-695.
PMID: 35919380
Purpose: During the last decade, [18F]F-choline positron emission tomography (PET) had a rising role in prostate cancer (PCa) imaging. However, despite auspicious premises, [18F]F-choline PET is not currently recommended for...
4.
Zattoni F, Artioli P, Burei M, Chiaravalloti A, Chierichetti F, Donner D, et al.
Q J Nucl Med Mol Imaging
. 2021 Sep;
67(2):167-173.
PMID: 34477346
Background: To assess the detection rate of 18F-choline PET/CT in non-metastatic hormone-sensitive prostate cancer (hsPCa) and non-metastatic castrate resistant prostate cancer (CRPCa), based on the criteria proposed in the phase...
5.
Evangelista L, Zattoni F, Cassarino G, Artioli P, Cecchin D, Dal Moro F, et al.
Eur J Nucl Med Mol Imaging
. 2020 Sep;
48(3):859-873.
PMID: 32901351
Aim: In recent years, the clinical availability of scanners for integrated positron emission tomography (PET) and magnetic resonance imaging (MRI) has enabled the practical potential of multimodal, combined metabolic-receptor, anatomical,...
6.
Olivari L, Riccardi N, Rodari P, Angheben A, Artioli P, Salgarello M
Eur J Nucl Med Mol Imaging
. 2020 Jun;
47(10):2476-2477.
PMID: 32500168
No abstract available.